(Q24201228)

2

object named as

Bi Rong Dong

0 references

author name string

Jirong Yue

1

0 references

Ming Yang

3

0 references

Xiaomei Chen

4

0 references

Guan J Liu

Cochrane Database of Systematic Reviews

6

0 references

publication date

12 July 2013

0 references

published in

0 references

cites work

Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008056.PUB2

Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008056.PUB2

Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008056.PUB2

Linezolid for the treatment of infections caused by Gram-positive pathogens in China

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008056.PUB2

Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008056.PUB2

Effect of Linezolid versus Vancomycin on Length of Hospital Stay in Patients with Complicated Skin and Soft Tissue Infections Caused by Known or Suspected Methicillin-Resistant Staphylococci: Results from a Randomized Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008056.PUB2

Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008056.PUB2

Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008056.PUB2

Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008056.PUB2

Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008056.PUB2

Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008056.PUB2

Linezolid eradicates MRSA better than vancomycin from surgical-site infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008056.PUB2

Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008056.PUB2

Linezolid versus vancomycin in the treatment of known or suspected resistant Gram-positive infections in neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008056.PUB2

Linezolid for the treatment of methicillin-resistant Staphylococcus aureus infections in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008056.PUB2

Linezolid for the treatment of complicated skin and skin structure infections in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008056.PUB2

Cost-effectiveness analysis of linezolid vs. vancomycin in treating methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections using a decision analytic model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008056.PUB2

Efficacy and safety of linezolid in the treatment of skin and soft tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008056.PUB2

Is linezolid superior to vancomycin for complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008056.PUB2

The role of diabetes mellitus in the treatment of skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus: results from three randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008056.PUB2

Cost-effectiveness of linezolid and vancomycin in the treatment of surgical site infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008056.PUB2

Cost-effectiveness of linezolid versus vancomycin for hospitalised patients with complicated skin and soft-tissue infections in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008056.PUB2

Linezolid versus vancomycin for the treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008056.PUB2

Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008056.PUB2

The existence of publication bias and risk factors for its occurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008056.PUB2

Linezolid versus vancomycin for MRSA skin and soft tissue infections (systematic review and meta-analysis).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008056.PUB2

Statistical methods for the meta-analysis of cluster randomization trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008056.PUB2

Treatment challenges in the management of complicated skin and soft-tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008056.PUB2

Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008056.PUB2

Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008056.PUB2

Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008056.PUB2

Linezolid: an oxazolidinone antimicrobial agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008056.PUB2

A practical guide to the treatment of complicated skin and soft tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008056.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008056.PUB2

Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008056.PUB2

Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008056.PUB2

Epidemiology of severe Streptococcus pyogenes disease in Europe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008056.PUB2

21 January 2018

Vancomycin: a history

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008056.PUB2

Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008056.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008056.PUB2

Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008056.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008056.PUB2

Practice guidelines for the diagnosis and management of skin and soft-tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008056.PUB2

Linezolid resistance in a clinical isolate of Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008056.PUB2

The oxazolidinone antibiotics perturb the ribosomal peptidyl-transferase center and effect tRNA positioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008056.PUB2

Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008056.PUB2

A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft-tissue infections caused by suspected or confirmed methicillin-resistant Staphylococcus aur

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008056.PUB2

7 January 2021

Managing skin and soft tissue infections: expert panel recommendations on key decision points

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008056.PUB2

7 January 2021

Safety and efficacy of glycopeptide antibiotics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008056.PUB2

7 January 2021

A novel antimicrobial agent joins the battle against resistant bacteria

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008056.PUB2

7 January 2021